41 results about "Melatonin agonist" patented technology

This invention provides methods of administering (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclo-propyl]methyl]propanamide as a melatonin receptor agonist to a human subject to treat or prevent a circadian rhythm disorder or sleep disorder.

A method of treating depression comprising administering a melatonin agonist.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

A method for achieving a chronobiologic effect on a circadian rhythm in a human infant or fetus in utero is described. The method involves the administration of melatonin or dose-equivalent melatonin analogue or melatonin receptor agonist to an infant by administering melatonin or dose-equivalent melatonin precursor, melatonin analogue or melatonin receptor agonist to the infant's breast-feeding mother or wet nurse, and to a fetus by administration of melatonin or dose-equivalent melatonin precursor, melatonin analogue or melatonin receptor agonist to the pregnant woman. Alternatives wherein melatonin or dose-equivalent melatonin analogue or melatonin receptor agonist is administered directly to the infant, such as in formula or in expressed breast milk, are also provided.

The invention provides novel indole alkaloid triglycoside shown in a structural formula (I), uncaria amide A (1), pharmaceutical composition comprising an effective quantity of compounds 1 for treatment and pharmaceutical carriers or excipients, a preparation method of the compounds 1 and the pharmaceutical composition containing the same as well as applications of the uncaria amide A as an MT (melatonin) receptor stimulant and in preparation of a drug for treating or relieving MT receptor related central nervous system diseases.

A pharmaceutical composition or kit of parts comprising at least three ingredients from a HMG-CoA reductase inhibitor, a leukotriene antagonist, a proton pump inhibitor, melatonin or a melatonin receptor agonist, a bioavailable preparation of a curcuminoid, a calciferol derivative, a compound from the group consisting of metformin and phenformin, valproate, minocycline and chloroquine and one or more pharmaceutically acceptable carriers or excipients.

A method of treating depression comprising administering a melatonin agonist.

The present invention relates to methods and compositions for the treatment or prevention of type 2 diabetes by administering an effective amount of a melatonin receptor agonist to a human subject in need of such treatment or prevention.

The invention relates to a pharmacologically active combination, having utility in treating insomnia patients, which comprises: (a) at least one first active ingredient selected from melatonin, other melatonergic agents, melatonin agonists and melatonin antagonists; and (b) at least one second active ingredient selected from nicotine and nicotine receptor agonists; to use of a medicament containing component (a) with or without component (b) for alleviation of at least one adverse effect which occurs in a patient in the course of nicotine replacement therapy, or otherwise, selected from impairment of the quality of sleep, impairment of cognition and impairment of memory, as well as to a kit having utility in treating insomnia patients, which comprises components (a) and (b) in unit dosage form.

The invention provides an application of catechin (1) shown as a structural formula (I) or pharmaceutical thereof and a pharmaceutical composition thereof in preparing a melatonin receptor agonist, anapplication thereof in preparing medicines for preventing or treating central nervous system disease related to melatonin receptor, and an application in preparing medicines for preventing or treating depression.

The invention provides application of magnolo-4-O-beta-D-glucopyranoside (1) shown as the structural formula (I) or medicinal salts and pharmaceutical compositions thereof to preparing melatonin receptor agonists as well as preparing drugs for treating or preventing central nervous system diseases correlated with melatonin receptors. The magnolo-4-O-beta-D-glucopyranoside (1) is prepared through achemical synthesis method.

Embodiments of the invention include the treatment of a sleep disorder comprising the administration of N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cycloproply]methyl]propanamide or a salt, stereoisomer, solvate, or hydrate thereof, in amorphous or crystalline form.

The invention provides four isoechinulin dimers (-)-uncarilins A(1a), (+)-uncarilins A(1b), (-)-uncarilin B(2a) and (+)-uncarilins B(2b) as shown in a structural formula (I), a pharmaceutical composition formed by a therapeutically effective amount of compound 1a / 1b or 2a / 2b and a pharmaceutically acceptable carrier or excipient, a preparation method of the compound 1a / 1b or 2a / 2b and the pharmaceutical composition thereof, a melatonin receptor agonist and an application of the isoechinulin dimmers in treatment or improvement of central nervous system diseases related to a melatonin receptor.

The invention relates to a pharmacologically active combination and a method of enhancing cognitive performance in a patient suffering from Alzheimer's disease comprising administering to said patient a cognitive performance-enhancing amount of melatonin or a melatonin agonist in a combination therapy with a nicotine receptor agonist.

The invention belongs to the technical field of drugs and provides magnolol derivatives (1-7) as shown in a structural formula (I) or a pharmaceutical composition and application of the magnolol derivatives or the pharmaceutical composition in preparing a melatonin receptor agonist as well as application thereof in preparing drugs for treating or preventing melatonin receptor related central nervous system diseases.

The invention provides a polybenzyl derivative (1-12) shown as a structural formula (I) or a drug composition of the polybenzyl derivative (1-12), a preparation method of the drug composition, and application of the drug composition to preparation of a melatonin receptor agonist and preparation of drugs for treating or preventing central nervous system diseases related to melatonin receptors.

The invention relates to N-(2-(substituted-naphth-1-yl)ethyl)-substituted amide compounds, and application of the same as melatonin receptor agonists and 5-HT2c receptor antagonists. Specifically, theinvention relates to the compounds as shown in a formula I which is described in the specification, or pharmaceutically acceptable salts or solvates thereof, or mixtures of the compounds, the salts and the solvates, and pharmaceutical compositions of the compounds, the salts, the solvates or the mixtures. X, R1, R2 in the formula I are as defined in the specification. The compounds as shown in the formula I of the invention can be used as melatonin receptor agonists and 5-HT2c receptor antagonists and is applicable to the preparation of drugs used for treating and / or preventing melatonin system diseases, stress, anxiety, seasonal affective disorders, cardiovascular diseases, digestive diseases, schizophrenia, phobias, depression, major depression, sleep disorders, sleep disturbance, insomnia or fatigue caused by jet lag, weight disorders and other diseases and illnesses.

The invention relates to a medicament, for treating and improving the restorative quality of sleep, in a patient suffering from primary insomnia, which comprises at least one compound selected from melatonin, other melatonergic agents, melatonin agonists and melatonin antagonists, in an effective amount within the range of 0.0025 to 50 mg, and optionally one or more other therapeutically active agents.

The invention provides a series of indole derivatives or stereoisomers, tautomers, nitrogen oxides, metabolic products and pharmaceutically acceptable salts or prodrugs thereof. The indole derivatives can be taken as melatonin receptor stimulants. The invention also discloses a pharmaceutical composition containing the compounds, and a use of the compounds or the pharmaceutical composition of the compounds in treating the functional disorder of the central nervous system of mammal and in particular human.

The present invention provides a method for treating a depressive disorder which comprises a dministering a melatonin agonist alone, or in combination wit additional ant idepressant medication(s). The depressive disorder treated is one or more of major depression, dysthymia or bipolar disorder. A kit is also provided com prising one or more pharmaceutical dose units of a melatonin agonist and oneor more pharmaceutical dose units of an antidepressant. The individual dose .units may each further comprise an antidepressant or antipsychotic, and opt ionally one or more pharmaceutically active ingredients.

The invention relates to a pharmacologically active combination and a method of enhancing cognitive performance in a patient suffering from Alzheimer's disease comprising administering to said patient a cognitive performance-enhancing amount of melatonin or a melatonin agonist in a combination therapy with a nicotine receptor agonist.

The invention provides a preparation method of a ramelteon orally disintegrating tablet. The orally disintegrating tablet, which takes ramelteon as an active ingredient, is a melatonin receptor agonist and is mainly used for treating insomnia of being hard to fall asleep, and the orally disintegrating tablet also has a concrete curative effect on chronic insomnia and short-term insomnia. The invention belongs to the novel technical field of medicines, and relates to the ramelteon orally disintegrating tablet and the preparation method thereof. The orally disintegrating tablet provided by the invention is good in taste and disintegrating effect and is good in stability; a sample is prepared by virtue of common equipment in accordance with a conventional process; and the preparation method is easy to operate, mature in process, low in production cost and is applicable to large-scale industrial production.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

The invention discloses an anti-insomnia composition, an application of the composition, a multi-phase pulse immediate-release preparation prepared by use of the composition and a preparation method of the preparation. The anti-insomnia composition consists of a component A and a component B, wherein the component A is one or more of melatonin, melatonin analogue and corresponding salt, melatonin receptor stimulant, 5-hydroxytryptamine 2C, receptor antagonist and 5-HTP (5-hydroxytryptophan); the component B is one or more of petroselinum neapolitanum extract, melissa extract, tuber fleeceflower stem extract, chamomile extract, passion flower extract, radix paeoniae alba extract, manyprickle acanthopanax extract, polygala tenuifolia extract, hyperforin perforatum extract, flos albiziae extract, lily extract and prunella vulgaris extract. The composition and the multi-phase pulse immediate-release preparation prepared by use of the composition have the characteristic of better anti-insomnia effect than a common melatonin preparation, and can effectively solve and improve the problem of difficult sleep of human or mammals while effectively solving and improving the insomnia problems such as light sleep or dreaminess or early awakening or difficult sleep after wakeup of human or mammals.